Mizolastine in the treatment of seasonal allergic rhinoconjunctivitis: A European clinical experience with 5408 patients managed in daily practice (PANEOS SAR study)

Allergy: European Journal of Allergy and Clinical Immunology

Volumn 56, Issue 7, 2001, Pages 653-659

  Bachert, C ^a   Vovolis, V ^b   Margari, P ^c   Murrieta Aguttes, M ^d   Santoni, J P ^d  

^a GHENT UNIVERSITY HOSPITAL   (Belgium)

^b SOTIRIA GENERAL HOSPITAL   (Greece)

^c ARISTOTLE UNIVERSITY OF THESSALONIKI   (Greece)

^d Sanofi Synthelabo Bagneux ^*  (France)

Author keywords

Mizolastine; Multicenter observational cohort study; Phase IV study; Seasonal allergic rhinoconjunctivitis

Indexed keywords

MIZOLASTINE; POLLEN ANTIGEN;

ADULT; ALERTNESS; ALLERGIC RHINITIS; ARTICLE; ASTHENIA; CLINICAL TRIAL; DROWSINESS; DRUG EFFICACY; DRUG SAFETY; FATIGUE; FEMALE; HEADACHE; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; POLLEN ALLERGY; PRIORITY JOURNAL; RHINOCONJUNCTIVITIS; SEASONAL VARIATION; SELF REPORT; SOMNOLENCE; SYMPTOM; XEROSTOMIA;

ADOLESCENT; ADULT; BENZIMIDAZOLES; CHILD; COHORT STUDIES; CONJUNCTIVITIS, ALLERGIC; EUROPE; FEMALE; HISTAMINE H1 ANTAGONISTS; HUMANS; INCIDENCE; MALE; MIDDLE AGED; RHINITIS, ALLERGIC, SEASONAL; TREATMENT OUTCOME;

EID: 0034979291     PISSN: 01054538     EISSN: None     Source Type: Journal    
DOI: 10.1034/j.1398-9995.2001.00756.x     Document Type: Article

References (23)

1. Prevalence of allergic rhinitis in the United States
2. The epidemiology of atopic diseases in Europe. A review
3. Is allergy increasing? early life influences
4. Assessment of quality of life in patients with perennial allergic rhinitis with the French version of the SF-36 Health Status Questionnaire
5. Work, classroom and activity impairment instruments, validation studies in allergic rhinitis
6. International consensus report on the diagnosis and management of rhinitis
7. Anti-inflammatory properties of mizolastine after oral administration on arachidonic acid-induced cutaneous reaction in the rat
8. Inhibitory effect of mizolastine on 5-lipoxygenase
9. Efficacy and safety of mizolastine in seasonal allergic rhinitis
10. Rapid and sustained efficacy of mizolastine 10 mg once daily in seasonal allergic rhinitis
11. Comparison of the efficacy, safety and onset of action of mizolastine, cetirizine and placebo in the management of seasonal allergic rhinoconjunctivitis
12. Mizolastine therapy also has an effect on nasal blockade in perennial allergic rhinoconjunctivitis
13. Efficacy of mizolastine, a new antihistamine, compared with placebo in the treatment of chronic idiopathic urticaria
14. Mizolastine is effective and well-tolerated in the long-term treatment of perennial allergic rhinoconjunctivitis
15. Efficacy and safety of mizolastine 10 mg in a placebo-controlled comparison with loratadine in chronic idiopathic urticaria: Results of the Milor study
16. Clinical research after drug approval: What is needed and what is not
17. Methods of studying antihistamines
18. Nasal congestion secondary to allergic rhinitis as a cause of sleep disturbance and daytime fatigue and the response to topical nasal corticosteroids
19. Clinical manifestations of the release of histamine and other inflammatory mediators
20. Sedation in allergic rhinitis is caused by the condition and not by antihistamine treatment
21. 1-receptor antagonist: Results of a pool of 30 clinical phase II, III, double-blind studies
22. New data on the safety of loratadine
23. Wirksamkeit und Sicherheit von Cetirizin bei allergischen Erkrankungen Ergebnisse einer Studie an 1.251 Patienten